Editing the Genome to Cure Genetic Disease

Casebia combines CRISPR/Cas9 expertise and technology from CRISPR Therapeutics with access to deep disease-state knowledge and protein engineering capabilities from Bayer. Our aim: to transform the lives of patients and families affected by genetic disease.

Social Media

Insightful review by Bluestone and Tang regarding the clinical potential of regulatory T-cells (#Tregs) as a new therapeutic modality for inflammatory diseases.

#CasebiaTx is in #Switzerland for the @ESGCT Annual Congress #ESGCT18 #ChangingModernMed

See us on Twitter